Real-World Data Confirm Utility of Lidocaine Medicated Plaster for Localized Peripheral Neuropathic Pain
Lidocaine medicated plaster effectively improved localized peripheral neuropathic pain.
Lidocaine medicated plaster effectively improved localized peripheral neuropathic pain.
A systematic review evaluated the efficacy of botulinum A toxin for chronic peripheral neuropathic pain.
CRPS was associated with temperature asymmetry, skin color asymmetry, asymmetric edema, motor changes, allodynia, and hyperalgesia.
Researchers used data from the State Unintentional Drug Overdose Reporting System in order to assess trends in gabapentin-involved overdose deaths.
This systematic review did not find any high quality evidence supporting the use of injectable biologics for neuropathic pain.
Using a constructed ANN model, researchers sought to predict the long-term outcomes of microvascular decompression surgery and the factors that influence prognosis in patients with trigeminal neuralgia.
Pain of any type was a relevant factor for the sequelae of chronic inflammatory demyelinating polyneuropathy.
A secondary analysis sought to identify predictors of pregabalin response in those with chronic posttraumatic neuropathic pain.
Presenting at the 2022 AAN Annual Meeting, researchers evaluated the safety and efficacy of vutrisiran using data from HELIOS-A, an ongoing, 18-month, phase 3 trial.
Researchers sought to evaluate patients with long COVID who had been referred for peripheral neuropathy evaluations.